
This memo lays out information for programs considering introducing improved first-line products and implementation guidance for transitioning to dolutegravir (DTG) as the preferred first-line regimen, in line with WHO treatment guidelines.
A framework to support new product introduction in national health systems
This memo lays out information for programs considering introducing improved first-line products and implementation guidance for transitioning to dolutegravir (DTG) as the preferred first-line regimen, in line with WHO treatment guidelines.